December 29, 2009 Amorfix corporate update: AMF currently developing six products with first sales for amyloid products already achieved and first test of vCJD patient samples
December 8, 2009 Envivo Pharmaceuticals Shows In-Vivo Reductions of Aggregated B-Amyloid using Amorfix A4 Test
December 4, 2009 Amorfix notifies warrant holders of extesion
November 13, 2009 Amorfix announces second quarter 2010 results
October 29, 2009 Amorfix blood test for vCJD completes testing at second blood center in France. 39,000 Blood Donations Tested to Date
October 27, 2009 Amorfix detects vCJD prions in blood from non-human primates
October 22, 2009 Amorfix offers unique antibodies and reagents for sale
October 19, 2009 Amorfix accelerates warrant expiry
October 1, 2009 Amorfix appoints Dr. Philippe Couillard to its board of directors
September 24, 2009 Amorfix blood test for vCJD to be featured at global forum on the safety and supply of treatment products for bleeding disorders
September 21, 2009 Amorfix blood test for vCJD continues to achieve excellent specificity on blood donations at second blood center in France
August 14, 2009 Amorfix announces fist quarter 2010 results
June 17, 2009 Tender Awarded to provide vCJD blood tests to UK blood transfusion service
June 15, 2009 Amorfix Launches Alzheimer's Amyloid Test At Scientific Conference In Vienna
June 24, 2009 Amorfix Test for vCJD Achieves 100% specificity on 20,000 blood donations in France
June 17, 2009 Amorfix Licenses Novel Theranostic Platform - PROMIS™
June 11, 2009 Amorfix Anounces 2009 Year End Results
May 20, 2009 Blood Transfusion Service in France Completes 20,000 Tests and Establishes Amorfix EP-vCJD™ Test in a Second Blood Center
April 29, 2009 Amorfix Closes $3.3 Million Private Placement
April 24, 2009 Amorfix Announces Private Placement
April 23, 2009 Amorfix and BioMosaics Collaborate to Develop a Blood Test for Liver Cancer Supported by Grant from the Ontario Institute for Cancer Research
April 20, 2009 Amorfix Corporate Update: AMF Expands Diagnostic and Therapeutic Focus to Include Misfolded Protein Diseases Including Cancer
February 20, 2009 Amorfix Extends Warrant Term by One Year
February 11, 2009 Amorfix Announces Fiscal 2009 Third Quarter Results
January 20, 2009 Amorfix Awarded "Life Science Company of the Year" for Moving Innovative Products into Commercialization
January 13, 2009 Large-Scale Testing Initiated in France with 10,000 Blood Samples Tested for vCJD - Amorfix Demonstrates vCJD Test Can Be Used Routinely to Test Blood Donations